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Background:  The  relationship  between  ongoing  myocardial  damage  and  heart  failure  with  preserved
left  ventricular  systolic  function  (HF-PEF)  is  still unclear.  To  investigate  this  relationship,  we  measured
the  cardiac-speciﬁc  cytosolic  marker,  heart-type  fatty  acid  binding  protein  (H-FABP),  and  a myoﬁbrillar
component  (troponin  T),  and  analyzed  clinical  outcomes.
Methods  and  results:  Consecutive  heart  failure  patients  (n = 151)  with  echocardiographic  left  ventricular
ejection  fraction  >50%  were prospectively  enrolled.  The  cut-off  values  for myocardial  membrane  injury
(H-FABP  >4.3  ng/mL)  and  myoﬁbrillar  injury  (troponin  T >0.01  ng/mL)  were  deﬁned  using  receiver oper-
ating characteristic  curves.  Myocardial  membrane  injury  was  observed  more  frequently  than  myoﬁbrillarroponin T injury  (41%  vs.  26%  of  patients,  p < 0.05).  Patients  were  followed  up  for  a  median  of 694  days,  with  the
end-points  being  cardiovascular  death  or re-hospitalization.  By multivariate  analysis,  the  serum  H-FABP
level was  an  independent  predictor  of  cardiovascular  events  (hazard  ratio  1.165  per  1 ng/mL increase,
95%  conﬁdence  interval  1.034–1.314,  p =  0.012).
Conclusions:  Latent  myocardial  injury  was  frequently  observed  in  patients  with  HF-PEF.  The  circulating
H-FABP  level  was  an  independent  predictor  of  subsequent  cardiovascular  events.
2  Jap© 201
ntroduction
Individuals with heart failure (HF) are at increased risk of recur-
ent symptomatic exacerbations, resulting in hospitalization or
eath. Most previous large studies on patients with HF were con-
ucted on those with low left ventricular ejection fraction (LVEF).
owever, there has been increased awareness in recent years that
any patients with symptomatic HF have a preserved ejection
raction (PEF) [1,2]. There are few data available on outcomes, or
uidelines for the management of patients with HF-PEF [3]. This
ack of information is problematic, because these patients are fre-
uently hospitalized or died due to worsening HF [4].  Earlier studies
uggested that the characteristics of patients with HF-PEF differed
rom those of patients with HF and reduced EF (HF-REF) [2–4], but
hat their rate of survival may  be as poor as that of patients with
F-REF [3–5].
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Multiple biomarkers have already been validated for HF-
REF and these markers are routinely used in clinical settings
[6,7]. Conversely, the prognostic biomarkers for HF-PEF have not
been sufﬁciently investigated. Ongoing myocardial damage and
progressive loss of cardiomyocytes play a critical role in the
pathophysiology and progression of HF-REF [8–13]. However, the
relationship between ongoing myocardial damage and HF-PEF is
still unclear. Knowledge of the underlying disease pathophysiol-
ogy may  help in the early identiﬁcation of individuals at risk of a
poor clinical outcome. To investigate this, we  measured the cardiac-
speciﬁc cytosolic marker, heart-type fatty acid binding protein
(H-FABP), and a myoﬁbrillar component (troponin T), and analyzed
clinical outcomes in patients with HF-PEF.
Methods
Study populationBetween January 2004 and September 2007, 350 consecu-
tive patients were admitted to Yamagata University Hospital for
treatment of worsening HF, for diagnosis and pathophysiological
investigations, or for therapeutic evaluation of HF. The diagnosis
vier Ltd. All rights reserved.
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f HF was based on a history of dyspnea and symptomatic exer-
ise intolerance, with signs of pulmonary congestion or peripheral
dema or documentation of LV enlargement or dysfunction, by
hest X-ray, echocardiography, or radionuclide ventriculography.
he clinical diagnosis of HF was conﬁrmed by at least two  cardi-
logists. Patients with acute decompensated HF, those diagnosed
ith acute coronary syndromes within the 3 months preceding
dmission, those with renal failure characterized by a serum creati-
ine concentration >2.0 mg/dL, those with congenital heart disease,
nd those with moderate or severe valvular heart disease, were
xcluded.
From this population, 151 consecutive patients with HF-PEF
LVEF ≥50%) (80 men, 71 women, mean age 69 ± 12 years, range
0–80) were prospectively enrolled in the study. The baseline
linical characteristics of 162 consecutive patients with HF-REF
LVEF <50%) (106 men, 56 women, mean age 67 ± 13 years, range
0–88) were also investigated as control subjects. Blood samples
ere obtained for measurement of serum H-FABP, troponin T, and
lasma brain natriuretic peptide (BNP) on the day of admission. An
xperienced cardiologist, who had no knowledge of the biochemi-
al data, performed two-dimensional echocardiography on the day
f blood sampling. Physicians were blinded to the results of the
iochemical analyses, and optimal medical therapy was  adminis-
ered independently, based on improvement in symptoms, physical
xamination, and chest X-ray ﬁndings [12]. Structural heart dis-
ases were diagnosed on the basis of echocardiographic ﬁndings,
adionuclide studies, cardiac catheterization studies, or coronary
ngiography. The glomerular ﬁltration rate (eGFR) was estimated
rom serum creatinine measurements, using the Japanese equation
hat takes into account the inﬂuence of age and gender on creatinine
roduction [14].
Written informed consent was provided by all patients prior to
articipation in the study, and the study protocol was  approved by
he institutional Human Investigations Committee.
easurement of H-FABP, troponin T, and BNP
Blood samples for measurement of serum levels of H-FABP and
roponin T were centrifuged at 2500 × g for 15 min  at 4 ◦C within
0 min  of collection, and the serum was stored at −70 ◦C until
nalysis. H-FABP levels were measured using a two-step sand-
ich enzyme-linked immunosorbent assay kit (MARKIT-M H-FABP,
ainippon Pharmaceutical Co. Ltd., Tokyo, Japan) [9,10,12]. The
alibrator samples for the enzyme-linked immunosorbent assay
overed the range of 0.1–250 ng/mL. Troponin T concentrations
ere measured using a third-generation electrochemilumines-
ent immunoassay on an Elecsys 2010 automatic analyzer
Elecsystroponin-T, Roche Diagnostics, Tokyo, Japan) [12]. The
ower limit of detection for this assay was 0.01 ng/mL. Blood sam-
les were also obtained at admission for measurement of BNP
lasma concentrations. These samples were transferred to chilled
ubes containing 4.5 mg  of ethylenediaminetetraacetic acid dis-
dium salt and aprotinin (500 U/mL), and centrifuged at 1000 × g
or 15 min  at 4 ◦C. The clariﬁed plasma samples were frozen, stored
t −70 ◦C, and thawed just before the assays were performed. BNP
oncentrations were measured using a commercially available spe-
iﬁc radioimmunoassay for human BNP (Shiono RIA BNP assay kit,
hionogi Co. Ltd., Tokyo, Japan) [10,12].  The analytical range of this
ssay was 4–2000 pg/mL.
ndpoints and follow-upNone of the patients were lost to follow-up after discharge
median follow-up period 694 days, range 29–2000). The endpoints
ere cardiovascular death (deﬁned as death due to progressivediology 60 (2012) 454–461 455
HF, myocardial infarction, stroke, other vascular causes, or sud-
den cardiac death), and progressive HF requiring re-hospitalization.
Sudden cardiac death was deﬁned as death without deﬁnite pre-
monitory symptoms or signs, and was  conﬁrmed by the attending
physician. Two cardiologists, who  were blinded to the blood
biomarker data conducted reviews of the medical records and
follow-up telephone interviews, to survey the incidence of car-
diovascular events. The incidence of cardiovascular events was
assessed from medical records, electrocardiograms, chest X-ray
reports, autopsy reports, death certiﬁcates, and witness statements
[9–13].
Statistical analysis
Continuous data are expressed as means ± standard deviation
(SD) and skewed data are presented as medians and interquartile
range. The t-test and chi-square test were used for comparisons
of continuous and categorical variables, respectively. When the
data were not normally distributed, the Mann–Whitney test was
used. Values for blood biomarker levels that were below the lower
detection limit of the assay were deﬁned as zero. Receiver operat-
ing characteristic (ROC) curves were constructed to determine the
cut-off values for the various biomarkers, as well as optimum sen-
sitivity and speciﬁcity. Areas under the ROC curves were calculated
using the trapezoidal rule. Univariate analysis and multivariate
analysis with Cox proportional hazard regression were used to
determine signiﬁcant predictors of cardiovascular events. Gender,
body mass index (BMI), eGFR, and variables that were signiﬁcant
in the univariate analyses were entered into the multivariate Cox
proportional hazard analysis. The cardiovascular event-free curves
were computed using the Kaplan–Meier method and were com-
pared using the log-rank test. A p-value <0.05 was considered
statistically signiﬁcant.
Results
Patient characteristics
The clinical characteristics of the 151 patients with HF-PEF and
the 162 patients with HF-REF are shown in Table 1. There were
42 patients in the New York Heart Association (NYHA) functional
class I, 162 in NYHA class II, and 109 in NYHA class III. The etiology
of HF was  identiﬁed as non-ischemic heart disease in 253 patients
(81%) and ischemic heart disease (history of myocardial infarction
or ischemic cardiomyopathy) in the remaining 60 patients (19%).
Cardiac catheterization and/or radionuclide studies conﬁrmed the
absence of signiﬁcant coronary stenosis or ischemic response in all
study subjects.
The group of patients with PEF included more females (p = 0.025)
and were more frequently diagnosed with hypertensive heart dis-
ease, valvular heart disease, and tachycardia-induced HF, when
compared with the group with REF (p < 0.001). Advanced NYHA
functional class was  more frequently observed in patients with
REF (p = 0.011). Although plasma BNP (p < 0.001), serum H-FABP
(p = 0.005), and serum high-sensitive C-reactive protein (hs-CRP)
levels (p = 0.001), LV end-diastolic diameter (p < 0.001), LV mass
index (p < 0.001), and E/A ratio (p = 0.005) were greater in the
patients with REF than those with PEF, presentation proﬁle, serum
troponin T level, and left atrial (LA) diameter did not differ between
the two groups. The patients with PEF received  blockers less
frequently (p = 0.041), but Ca-channel blockers more frequently
(p < 0.001), than those with REF (Table 1).
In patients with HF-PEF, serum levels of H-FABP ranged from
0.5 to 24 ng/mL (median 3.8 ng/mL), serum levels of troponin T
ranged from <0.01 to 0.22 ng/mL (median 0.01 ng/mL), and BNP
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Table 1
Baseline clinical characteristics.
All patients
(n = 313)
HF-PEF
(n = 151)
HF-REF
(n = 162)
p-Value
Age, years 67 ± 13 69 ± 12 67 ± 13 0.088
Female, n (%) 127 (41) 71 (47) 56 (35) 0.025
NYHA  functional class, I/II/III 42/162/109 22/89/40 20/73/69 0.011
Etiology, n (%) <0.001
Dilated cardiomyopathy 81 (26) 0 81 (50)
Hypertensive heart disease 80 (26) 70 (46) 10 (6)
Ischemic heart disease 60 (19) 22 (15) 38 (24)
Valvular heart disease 45 (14) 29 (19) 16 (10)
Tachycardia-induced heart failure 26 (8) 18 (12) 8 (5)
Other 21 (7) 12 (8) 9 (5)
Atrial ﬁbrillation, n (%) 108 (35) 54 (36) 54 (33) 0.710
Diabetes mellitus, n (%) 84 (27) 37 (25) 47 (29) 0.334
Dyslipidemia, n (%) 78 (25) 35 (23) 43 (27) 0.452
Current smoker, n (%) 83 (27) 34 (23) 49 (30) 0.079
Presentation proﬁle
Systolic pressure, mm Hg 117 ± 20 117 ± 21 118 ± 17 0.838
Heart  rate, bpm 70 ± 14 71 ± 14 69 ± 14 0.351
Body  mass index, kg/m2 22.7 ± 3.5 23.1 ± 3.3 22.5 ± 3.7 0.149
eGFR,  mL/min/1.73 m2 66 ± 22 67 ± 21 64 ± 23 0.284
Blood  biomarkers
BNP, pg/mL (IQR) 186 (76–584) 124 (51–332) 328 (126–846) <0.001
Troponin T, ng/mL (IQR) 0.01 (0.01–0.02) 0.01 (0.01–0.02) 0.01 (0.01–0.03) 0.261
H-FABP, ng/mL (IQR) 4.3 (2.9–6.6) 3.8 (2.8–6.1) 5.0 (3.1–7.8) 0.005
High  sensitive CRP, mg/dL (IQR) 0.18 (0.09–0.519) 0.12 (0.06–0.40) 0.20 (0.10–0.60) 0.001
Echocardiographic data
LA diameter, mm 43.7 ± 7.8 43.7 ± 8.4 43.8 ± 7.2 0.878
LV  end-diastolic diameter, mm 54.1 ± 9.9 49.3 ± 8.8 58.6 ± 8.7 <0.001
LV  ejection fraction, % 49.1 ± 18.4 65.4 ± 9.2 33.8 ± 9.7 <0.001
LV  mass index, g/m2 190 ± 68 176 ± 60 203 ± 71 <0.001
E/A  ratio 1.14 ± 0.84 0.95 ± 0.54 1.29 ± 1.01 0.005
Medications, n (%)
ACE inhibitors and/or ARBs 216 (69) 97 (64) 119 (73) 0.078
 Blockers 124 (40) 51 (34) 73 (45) 0.041
Ca  channel blockers 62 (20) 42 (28) 20 (12) <0.001
Data are presented as mean ± SD or % unless otherwise indicated. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide;
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the prevalence of atrial ﬁbrillation, LA diameter, and E/A ratio were
signiﬁcantly greater in patients with high H-FABP levels than in
those with low H-FABP levels (Table 2), these differences were not
Class I Cla ss II  Cla ss III 
NYHA functional  cl ass  
0 
4 
8 
12 
16 
p=0.347  
PEF 
REF 
H-FABP (ng/mL) 
p=0.484  
p=0.212  RP,  C-reactive protein; eGFR, estimated glomerular ﬁltration rate; HF, heart failur
V,  left ventricular; NYHA, New York Heart Association; PEF, preserved ejection fra
lasma levels ranged from 6 to 1920 pg/mL (median 124 pg/mL)
Table 1). In patients with HF-REF, serum levels of H-FABP ranged
rom 0.1 to 31 ng/mL (median 5.0 ng/mL), serum levels of troponin T
anged from <0.01 to 1.45 ng/mL (median 0.01 ng/mL), and plasma
evels of BNP ranged from 6 to 2000 pg/mL (median 328 pg/mL)
Table 1).
Serum H-FABP levels increased with advancing NYHA functional
lass, both in patients with HF-PEF and in those with HF-REF. How-
ver, serum levels of H-FABP did not differ between each NYHA
unctional class (Fig. 1).
linical features of patients with ongoing myocardial damage
The cut-off values used in this analysis were 4.3 ng/mL for H-
ABP, and 0.01 ng/mL for troponin T. Myocardial membrane injury,
s deﬁned by elevated H-FABP levels (>4.3 ng/mL), was more fre-
uently observed than myoﬁbrillar injury, as deﬁned by elevated
roponin T levels (>0.01 ng/mL), in patients with HF-PEF (41% vs.
6% of patients, p < 0.05). When either H-FABP or troponin T levels
ere above the cut-off values, patients with HF were consid-
red to have ongoing myocardial damage [12]. There were 62
F patients with elevated serum H-FABP levels (Table 2), and
9 HF patients with elevated serum troponin T levels (Table 3).
atients with ongoing myocardial damage were older, were in a
ore severe NYHA functional class, had a lower mean BMI, worse
enal function, higher levels of BNP, troponin T, H-FABP, and hs-
RP, and were treated with  blockers more frequently than those
ithout myocardial damage. The etiology of HF did not differABP, heart-type fatty acid-binding protein; IQR, interquartile range; LA, left atrial;
 REF, reduced ejection fraction.
between patients with or without ongoing myocardial damage.
Echocardiographic ﬁndings, LV end-diastolic diameter, LVEF, and
LV mass index did not differ between the two  groups. AlthoughFig. 1. Serum levels of heart-type fatty acid binding protein (H-FABP) in patients
with heart failure and preserved ejection fraction (PEF) or reduced ejection fraction
(REF). H-FABP levels did not differ between patients in different New York Heart
Association (NYHA) functional classes.
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Table  2
Clinical characteristics of the patients with heart failure, preserved ejection fraction and high or low heart-type fatty acid binding protein levels.
High H-FABP
(n = 62)
Low H-FABP
(n = 89)
p-Value
Age, years 74 ± 8 64 ± 13 <0.001
Female, n (%) 32 (52) 39 (44) 0.345
NYHA  functional class, I/II/III 1/35/26 21/54/14 <0.001
Etiology, n (%) 0.228
Hypertensive heart disease 29 (46) 41 (46)
Valvular heart disease 10 (16) 19 (21)
Ischemic heart disease 6 (10) 16 (18)
Tachycardia-induced heart failure 11 (18) 7 (8)
Other 6 (10) 6 (7)
Atrial  ﬁbrillation, n (%) 29 (47) 25 (28) 0.018
Diabetes mellitus, n (%) 13 (21) 24 (27) 0.392
Dyslipidemia, n (%) 13 (21) 22 (25) 0.591
Current smoker, n (%) 14 (23) 20 (22) 0.987
Presentation proﬁle
Systolic pressure, mm Hg 115 ± 22 118 ± 22 0.430
Heart  rate, bpm 71 ± 13 71 ± 14 0.975
Body  mass index, kg/m2 22.3 ± 3.7 23.7 ± 2.9 0.009
eGFR, mL/min/1.73 m2 58 ± 18 73 ± 20 <0.001
Blood  biomarkers
BNP, pg/mL (IQR) 235 (89–593) 90 (38–210) <0.001
Troponin T, ng/mL (IQR) 0.01 (0.01–0.05) 0.01 (0.01–0.01) 0.012
H-FABP, ng/mL (IQR) 6.6 (5.2–8.4) 2.9 (2.2–3.5) <0.001
High  sensitive CRP, mg/dL (IQR) 0.29 (0.08–0.67) 0.10 (0.05–0.29) <0.001
Echocardiographic data
LA diameter, mm 45.8 ± 10.2 42.1 ± 6.4 0.009
LV  end-diastolic diameter, mm 48.4 ± 7.5 49.9 ± 9.7 0.326
LV  ejection fraction, % 65.1 ± 9.7 65.6 ± 8.9 0.737
LV  mass index, g/m2 181 ± 59 172 ± 61 0.409
E/A  ratio 1.19 ± 0.69 0.82 ± 0.38 0.002
Medications, n (%)
ACE inhibitors and/or ARBs 42 (68) 55 (62) 0.453
  Blockers 28 (45) 23 (26) 0.014
Ca  channel blockers 13 (21) 29 (33) 0.117
Data are presented as mean ± SD or % unless otherwise indicated. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide;
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all cardiovascular events, compared with those in the lowest ter-
tile of H-FABP (0.5–3.0 ng/mL) [hazard ratio 4.394, 95% conﬁdence
interval (CI) 1.967–9.815, p < 0.001]. Patients in the third tertile of
H-FABP were older, were in a more severe NYHA functional class,
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Fig. 2. Kaplan–Meier curves showing cardiac event-free survival in patients withRP,  C-reactive protein; eGFR, estimated glomerular ﬁltration rate; H-FABP, heart-ty
YHA, New York Heart Association.
pparent in patients with high troponin T levels, compared to those
ith low troponin T levels (Table 3).
orrelation between biomarkers and other variables measured
The correlations between biomarker levels and other vari-
bles measured were assessed (Table 4). Serum H-FABP levels
ere weakly correlated with age (r = 0.371, p < 0.001) and eGFR
r = −0.295, p < 0.001). Weak relationships were also observed
etween H-FABP levels and LA diameter (r = 0.326, p < 0.001) and
/A ratio (r = 0.273, p = 0.01). However, serum H-FABP levels were
ot correlated with LV parameters, including LV end-diastolic
iameter, LVEF, or LV mass index. Serum troponin T levels were
eakly correlated with eGFR (r = −0.264, p = 0.026). However, tro-
onin T levels were not correlated with echocardiographic ﬁndings.
lasma BNP levels were weakly correlated with age (r = 0.184,
 = 0.024), eGFR (r = −0.239, p = 0.003), LV mass index (r = 0.322,
 < 0.001), and E/A ratio (r = 0.261, p = 0.014).
redictors of subsequent cardiovascular events
During the follow-up period, cardiovascular events were
bserved in 42 of 151 patients (28%). These included 17 cardio-
ascular deaths (12 due to progression of HF, 3 due to myocardial
nfarction, 1 due to stroke, and 1 sudden death), and 25 re-
ospitalizations for worsening HF. By univariate Cox analysis, age,
YHA functional class, the presence of atrial ﬁbrillation, plasma
NP levels, serum H-FABP levels, and LA diameter were signiﬁ-
antly associated with cardiovascular events (Table 5). Multivariatety acid-binding protein; IQR, interquartile range; LA, left atrial; LV, left ventricular;
Cox analysis revealed that only the serum H-FABP level was an inde-
pendent predictor of cardiovascular events (Table 5). Kaplan–Meier
survival curves showed that patients in the highest tertile of H-
FABP had a signiﬁcantly increased risk of adverse cardiovascular
events (log-rank test p < 0.001; Fig. 2). Patients in the third ter-
tile of H-FABP (5.0–24 ng/mL) had a signiﬁcantly increased risk ofheart failure and preserved ejection fraction, according to tertiles of heart-type
fatty acid binding protein (H-FABP). All cardiac events at 5 years: 15.7% for patients
in  the ﬁrst tertile of H-FABP (0.5–3.0 ng/mL), 16.0% for patients in the second ter-
tile of H-FABP (3.1–4.9 ng/mL), and 47.0% for patients in the third tertile of H-FABP
(5.0–24 ng/mL). Log rank p < 0.001.
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Table 3
Clinical characteristics of the patients with heart failure, preserved ejection fraction and high or low troponin T levels.
High troponin T
(n = 39)
Low troponin T
(n = 112)
p-Value
Age, years 74 ± 10 67 ± 12 0.001
Female, n (%) 20 (51) 51 (46) 0.395
NYHA functional class, I/II/III 0/21/18 22/68/22 <0.001
Etiology, n (%) 0.306
Hypertensive heart disease 20 (51) 50 (45)
Valvular heart disease 6 (15) 23 (21)
Ischemic heart disease 4 (10) 18 (16)
Tachycardia-induced heart failure 7 (18) 11 (10)
Other 2 (5) 10 (9)
Atrial ﬁbrillation, n (%) 17 (44) 37 (33) 0.162
Diabetes mellitus, n (%) 7 (18) 30 (28) 0.126
Dyslipidemia, n (%) 7 (18) 28 (25) 0.196
Current smoking, n (%) 7 (18) 27 (24) 0.240
Presentation proﬁle
Systolic pressure, mm Hg 116 ± 23 118 ± 21 0.690
Heart  rate, bpm 70 ± 13 71 ± 14 0.530
Body  mass index, kg/m2 22.0 ± 3.6 23.6 ± 3.1 0.006
eGFR, mL/min/1.73 m2 56 ± 19 72 ± 19 <0.0001
Blood  biomarkers
BNP, pg/mL (IQR) 167 (83–584) 112 (41–260) 0.013
Troponin T, ng/mL (IQR) 0.06 (0.04–0.16) 0.01 (0.01–0.01) <0.001
H-FABP, ng/mL (IQR) 6.8 (5.3–8.4) 3.1 (2.5–4.0) <0.001
High  sensitive CRP, mg/dL (IQR) 0.30 (0.10–0.68) 0.10 (0.05–0.30) 0.002
Echocardiographic data
LA diameter, mm 45.3 ± 10.8 42.9 ± 7.0 0.114
LV  end-diastolic diameter, mm 47.6 ± 6.7 50.0 ± 9.6 0.120
LV  ejection fraction, % 65.4 ± 9.3 65.4 ± 9.1 0.995
LV  mass index, g/m2 186 ± 54 171 ± 63 0.163
E/A  ratio 1.11 ± 0.56 0.89 ± 0.52 0.079
Medications, n (%)
ACE inhibitors and/or ARBs 29 (74) 68 (61) 0.060
  Blockers 18 (46) 33 (29) 0.032
Ca  channel blockers 7 (18) 35 (31) 0.090
Data are presented as mean ± SD or % unless otherwise indicated. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide;
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ad worse renal function, higher levels of BNP, troponin T, H-FABP,
nd hs-CRP, and were treated with  blockers more frequently than
hose in the lower tertile of H-FABP. Echocardiographic ﬁndings
howed that patients in the highest tertile of H-FABP had higher
/A ratios than in those with lower H-FABP levels (Table 6).
iscussion
ain ﬁndings
The ﬁndings from this study were as follows: (1) Latent myocar-
ial injury was frequently observed in patients with HF-PEF.
yocardial membrane injury was more frequently observed than
yoﬁbrillar injury. (2) The serum level of H-FABP was an indepen-
ent predictor of subsequent cardiovascular events.
able 4
elationships between clinical parameters and biomarkers in patients with heart failure 
H-FABP 
r p-Value 
Age 0.371 <0.001 
eGFR  −0.295 <0.001 
Echocardiographic data
LA diameter 0.326 <0.001 
LV  end-diastolic diameter −0.039 0.639 
LV  ejection fraction −0.010 0.906 
LV  mass index 0.082 0.334 
E/A  ratio 0.273 0.010 
NP, brain natriuretic peptide; eGFR, estimated glomerular ﬁltration rate; H-FABP, heart-tty acid-binding protein; IQR, interquartile range; LA, left atrial; LV, left ventricular;
Ongoing myocardial damage in patients with HF-PEF
Although many large cohort studies have shown that HF-PEF
predominantly afﬂicts elderly, hypertensive patients [1–5], the
pathophysiological differences between HF-PEF and HF-REF remain
poorly elucidated. The current understanding of the progression
of HF-REF invokes progressive ventricular remodeling in response
to myocardial injury [15,16]. Several factors, including ischemic
myocardial damage, activation of sympathetic nerve function,
inﬂammatory processes, and autophagic degeneration, have been
implicated in myocyte injury and death. All these pathways con-
verge on myocardial damage and death by progressive necrosis or
apoptosis [15–17].
Importantly, the results clearly show that latent myocardial
injury was frequently observed in patients with HF-PEF. These
results imply that myocardial injury is important in HF-PEF.
and preserved ejection fraction.
Troponin T BNP
r p-Value r p-Value
0.019 0.878 0.184 0.024
−0.264 0.026 −0.239 0.003
0.060 0.622 0.108 0.206
−0.068 0.571 0.012 0.889
0.002 0.985 0.005 0.952
0.170 0.160 0.322 <0.001
0.165 0.280 0.261 0.014
type fatty acid-binding protein; LA, left atrial; LV, left ventricular.
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Table  5
Univariate and multivariate analyses of factors predicting cardiovascular events in patients with heart failure and preserved ejection fraction.
Univariate analysis Multivariate analysis
HR 95% CI of HR p-Value HR 95% CI of HR p-Value
Age, per 10-year increase 1.616 1.015–1.086 0.005 1.296 0.983–1.072 0.239
Female gender 1.254 0.674–2.333 0.476 1.142 0.474–2.753 0.767
NYHA  functional class III 3.752 1.995–7.057 <0.001 2.103 0.749–5.903 0.158
Presence of
Atrial ﬁbrillation 2.132 1.142–3.982 0.018 0.971 0.357–2.642 0.955
Diabetes mellitus 1.445 0.733–2.847 0.288
Dyslipidemia 1.089 0.532–2.230 0.815
Presentation proﬁle
Systolic pressure, per SD increase 0.887 0.981–1.006 0.328
Heart rate, per SD increase 1.251 0.992–1.041 0.205
Body mass index, per SD increase 0.900 0.867–1.081 0.568 0.903 0.850–1.107 0.649
eGFR, per SD increase 0.803 0.973–1.007 0.233 1.013 0.977–1.023 0.996
Blood  biomarkers
BNP, per 100 pg/mL increase 1.105 1.000–1.001 0.011 1.030 0.999–1.001 0.552
Troponin T, per 0.01 ng/mL increase 1.990 0.849–4.665 0.113
H-FABP, per 1 ng/mL increase 1.198 1.122–1.279 <0.001 1.165 1.034–1.314 0.012
High  sensitive CRP, per 0.1 mg/dL increase 1.029 0.914–1.921 0.137
Echocardiographic data
LA diameter, per SD increase 1.641 1.002–1.122 0.041 1.244 0.957–1.101 0.461
LV  end-diastolic diameter, per SD increase 0.817 0.941–1.014 0.218
LV  ejection fraction, per SD increase 1.191 0.986–1.053 0.262
LV  mass index, per SD increase 1.197 0.998–1.008 0.285
E/A ratio, per SD increase 1.376 0.915–3.561 0.088
Medications
ACE inhibitors and/or ARBs 1.036 0.534–1.992 0.915
 Blockers 1.159 0.604–2.221 0.657
Ca  channel blockers 0.895 0.454–1.764 0.749
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; CI, conﬁdence interval; CRP, C-reactive protein; eGFR, estimated
glomerular ﬁltration rate; H-FABP, heart-type fatty acid-binding protein; HR, hazard ratio; LA, left atrial; LV, left ventricular; NYHA, New York Heart Association; SD,  standard
deviation.
Table  6
Clinical characteristics by tertile of heart-type fatty acid binding protein levels in patients with heart failure and preserved ejection fraction.
1st tertile H-FABP 0.5–3.0 ng/mL
(n  = 50)
2nd tertile H-FABP 3.1–4.9 ng/mL
(n = 50)
3rd tertile H-FABP 5.0–24 ng/mL
(n  = 51)
p-Value
Age, years 61 ± 14 71 ± 8 73 ± 8 <0.001
Female, n (%) 24 (48) 22 (44) 25 (49) 0.868
NYHA  functional class, I/II/III 20/23/7 1/39/10 1/27/23 <0.001
Etiology, n (%) 0.214
Hypertensive heart disease 21 (42) 24 (48) 25 (49)
Ischemic heart disease 8 (16) 9 (18) 5 (10)
Valvular heart disease 15 (30) 7 (14) 7 (14)
Tachycardia-induced heart failure 2 (4) 7 (14) 9 (18)
Other 4 (8) 3 (6) 5 (10)
Atrial ﬁbrillation, n (%) 15 (30) 19 (38) 20 (39) 0.578
Diabetes mellitus, n (%) 11 (22) 15 (30) 11 (22) 0.542
Dyslipidemia, n (%) 13 (26) 13 (26) 9 (18) 0.516
Current smoker, n (%) 13 (26) 11 (22) 10 (20) 0.079
Presentation proﬁle
Systolic pressure, mm Hg 114 ± 23 123 ± 18 114 ± 23 0.073
Heart  rate, bpm 69 ± 13 74 ± 14 70 ± 13 0.154
Body  mass index, kg/m2 23.4 ± 2.5 23.7 ± 3.2 22.2 ± 3.8 0.054
eGFR,  mL/min/1.73 m2 79 ± 19 63 ± 18 58 ± 19 <0.001
Blood  biomarkers
BNP, pg/mL (IQR) 112 (38–253) 93 (43–215) 250 (86–589) 0.006
Troponin T, ng/mL (IQR) 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.05 (0.02–0.16) <0.001
H-FABP, ng/mL (IQR) 2.4 (1.8–2.8) 3.8 (3.4–4.3) 6.9 (6.1–9.1) <0.001
High  sensitive CRP, mg/dL (IQR) 0.10 (0.04–0.27) 0.10 (0.05–0.24) 0.32 (0.12–0.79) <0.001
Echocardiographic data
LA diameter, mm 42.6 ± 6.5 42.5 ± 6.4 45.8 ± 11.1 0.094
LV  end-diastolic diameter, mm 51.8 ± 9.6 47.1 ± 8.9 49.0 ± 7.5 0.127
LV  ejection fraction, % 65.1 ± 9.6 67.0 ± 7.6 64.3 ± 10.1 0.315
LV  mass index, g/m2 181 ± 66 160 ± 53 187 ± 59 0.069
E/A  ratio 0.90 ± 0.43 0.74 ± 0.32 1.21 ± 0.69 0.002
Medications, n (%)
ACE inhibitors and/or ARBs 28 (56) 33 (66) 36 (71) 0.295
  Blockers 14 (28) 13 (26) 24 (47) 0.047
Ca  channel blockers 13 (26) 17 (34) 12 (24) 0.472
Data are presented as mean ± SD or % unless otherwise indicated. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide;
CRP,  C-reactive protein; eGFR, estimated glomerular ﬁltration rate; H-FABP, heart-type fatty acid-binding protein; IQR, interquartile range; LA, left atrial; LV, left ventricular;
NYHA, New York Heart Association.
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nfortunately, the detailed processes involved in myocardial cell
eath in patients with HF-PEF have not been fully clariﬁed. How-
ver, at least in the present study, ischemic myocardial injury was
ot associated with myocardial damage. A large number of patients
ith ischemic heart disease were included among those without
ngoing myocardial damage. In agreement with previous reports
9–13], age, being in NYHA functional class III, renal function,
nd plasma BNP levels were associated with ongoing myocardial
amage. The present ﬁndings, therefore, conﬁrmed the close rela-
ionship between advanced HF and latent myocardial damage in
atients with HF-PEF.
ngoing myocardial damage and LV function
Progressive loss of myocytes is recognized as one of the patho-
hysiological mechanisms in the evolution of cardiac dysfunction
n HF [15–17].  Latent loss of cardiomyocytes was detected clinically
s increased serum levels of H-FABP and cardiac troponins. Previous
tudies conﬁrmed a signiﬁcant correlation between serum troponin
evels and LV function [18,19]. However, in the present study, serum
roponin T levels were not correlated with any echocardiographic
arameters. One explanation for these different ﬁndings may  be
hat troponin T levels were only measured once during the study
eriod. Indeed, LVEF decreased by 5.9% in patients with high tro-
onin T levels compared to those with normal troponin T levels,
uring a follow-up period of 20.8 ± 11.2 months [20]. Follow-up
easurements of troponin T and echocardiographic ﬁndings may
rovide additional information on cardiac function.
The association between H-FABP and LV function has not been
lariﬁed. Serum H-FABP levels were also not correlated with LVEF,
V end-diastolic diameter, or LV mass index in patients with HF-
EF. Conversely, weak correlations were observed between serum
-FABP levels and LA diameter, and E/A ratio. There was a signiﬁ-
ant association between circulating H-FABP levels and LV diastolic
unction. As well as measuring cardiac troponin, additional mea-
urements of H-FABP may  be necessary to accurately assess the
elationship between serum H-FABP levels and cardiac function.
rognostic value of H-FABP in patients with HF-PEF
This study conﬁrmed the superior sensitivity of H-FABP com-
ared with that of troponin T, as demonstrated in this and earlier
tudies [12,21,22].  Basic and clinical research, using rats and human
utopsy cases, revealed that leakage of H-FABP occurred despite the
bsence of myocyte necrosis [21]. H-FABP is a low molecular weight
rotein that is conﬁned to the cytoplasm, and is released into the
irculation through the porous membranes of damaged myocardial
ells [22].
An association between BNP and outcomes in patients with HF-
EF has been reported previously [23,24]. Conversely, BNP did not
ndependently predict cardiovascular events in the present study.
ossible explanations for these different ﬁndings may  be that H-
ABP is not only just a marker of myocardial damage, but may  also
e a biomarker for several clinical characteristics. Consistent with
ur results, a large community-based population study demon-
trated that serum H-FABP levels were associated with age, gender,
nd renal function [25]. In addition, circulating H-FABP levels were
igniﬁcantly correlated with cardiac sympathetic dysfunction [26].
oreover, serum H-FABP levels were weakly correlated with LA
iameter and E/A ratio, which are indicators of LV diastolic dys-
unction. On the other hand, neither troponin T nor BNP levels were
orrelated with LA diameter. A persistent increase in LA ﬁlling pres-
ure leads to dilation of the chamber and stretching of the atrial
yocardium. Increased LA size is a more sensitive prognostic indi-
ator than BNP levels in HF patients [27]. Several clinical indicators
hat provide prognostic information were signiﬁcantly associateddiology 60 (2012) 454–461
with serum levels of H-FABP. Therefore, H-FABP may  be a more
sensitive prognostic indicator than troponin T and BNP levels in
patients with HF-PEF.
H-FABP levels were categorized into tertiles because the normal
range for H-FABP in patients with HF-PEF has not been established.
Although, in the adjusted model, there was  no difference between
patients in the ﬁrst and second tertiles of H-FABP, patients in the
highest tertile had a 4.4-fold increased risk of cardiac events. In this
regard, awareness of latent myocardial damage is important during
long-term follow-up of patients with HF-PEF, especially in patients
with H-FABP levels >5.0 ng/mL.
Study limitations
First, this single-center study included a population of referred
HF patients. Therefore, the characteristics of these patients with HF-
PEF differed from those of patients enrolled in community-based
studies. This study population showed a relatively high proportion
of patients with valvular heart disease and tachycardia-induced
cardiomyopathy. This study did not include patients with congen-
ital heart disease and moderate or severe valvular heart disease.
Second, the present ﬁndings in patients with HF-PEF may  not
be applicable to patients with severe HF. Consistent with previ-
ous research, the circulating level of H-FABP, but not BNP, was
a predictor of cardiovascular events in patients with early stage
HF [11]. However, BNP may  also have better prognostic accu-
racy in other clinical settings. Third, detailed echocardiographic
assessments were not performed in the present study. Patients
with myocardial damage had higher E/A ratios than those without
myocardial damage. This is referred to as the pseudonormalized
mitral ﬂow ﬁlling pattern, and may represent a moderate stage
of diastolic dysfunction in patients with high levels of H-FABP.
Advanced echocardiography may  help to clarify the relationship
between ongoing myocardial damage and LV diastolic function in
patients with HF-PEF. Finally, serum H-FABP levels were measured
once on the day of admission. Although patients with acute decom-
pensated HF were excluded, serum H-FABP levels in patients in
NYHA functional class III may  be correlated with volume over-
load/wall stress in the setting of acute heart failure. Additional
measurements of H-FABP may  provide useful information during
follow-up.
Conclusions
Ongoing myocardial injury was  frequently observed in patients
with HF-PEF. Circulating H-FABP level was a signiﬁcant predic-
tor for increased risk of cardiovascular events in patients with
HF-PEF. H-FABP may  be a novel, useful biomarker for identify-
ing patients with HF-PEF, who are at increased risk of death and
re-hospitalization.
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